arrow
M

Marcello Maugeri-Saccà

IRCCS Regina Elena National Cancer Institute
H指数:37
被引数:4,933

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study

铂类新辅助化疗及DNA损伤反应生物标志物在TNBC中的预测作用:NeoCarbo研究

2026-05-290
OAAI
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer

DNA甲基转移酶3A(DNMT3A)突变与非小细胞肺癌中PD-(L)1阻断疗法的疗效

2025-06-180
PRE
Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets

肺神经内分泌肿瘤的遗传学见解:Notch和Wnt信号通路作为潜在靶点

2025-05-140
OA
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

黏液性组织学特征的肺腺癌:临床、基因组学和免疫微环境特征及对基于免疫疗法治疗和KRASG12C抑制剂的疗效

2025-03-014
PRE
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

DARPP-32和t-darpp在anti-HER2药物抗性发展中的作用。STEP研究的临床前证据

2023-11-011
OAAI
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

里贾纳·埃琳娜国家癌症研究所的分子肿瘤委员会: 从应计到现实世界的治疗

2023-10-164
OAAI
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
2023-03-0112
OAAI
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI